Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA-seq data from patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy in soft tissue carcoma

ABSTRACT: We have employed single cell sequencing data to study the tumor microenvironment in patients with soft tissue sarcoma. This includes longitudinal biopsy and surgical specimens during a phase 1 clinical trial (NCT04420975) testing pre-operative hypofractionated radiation therapy with BO-112 (Highlight Therapeutics). As a comparison, we included surgical specimens from a cohort of patients undergoing pre-operative hypofractionated radiation therapy alone (NCT02701153).

ORGANISM(S): Homo sapiens

PROVIDER: GSE313859 | GEO | 2026/01/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Spatial transcriptomic data from longitudinal tumor samples from one patient undergoing neoadjuvant BO-112 and hypofractionated radiation therapy in soft tissue carcoma

Project description:We have employed spatial transcriptomic data to study the tumor microenvironment in a single patient with soft tissue sarcoma over time during treatment with hypofractionated preoperative radiation and intratumoral BO-112.

2026-01-05 | GSE313858 | GEO

Bulk RNA-sequencing of soft tissue sarcomas from patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma

Project description:Patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma were sequenced to identify changes in gene expression and pathway differences across different timepoints and treatments

2026-02-17 | GSE319794 | GEO

Single-cell RNA-sequencing of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and liposarcoma samples from patients participating in a clinical trial studying BO-112 plus Nivolumab and hypofractionated pre-operative radiotherapy.

Project description:Here we analyzed through single cell RNA sequencing multiple samples derived from patients with three different types of soft tissue sarcoma, including liposarcoma, undifferentiated pleomorphic sarcoma, and myxofibrosarcoma, participating in a clinical trial that evaluates the efficacy of intra-tumoral BO-112 injection with or without Nivolumab and pre-operative radiation therapy. The goal of this study is to analyze the changes in the tumor-microenvironment associated with the treatments administered.

2025-07-15 | GSE279852 | GEO

Bulk RNA-sequencing of four soft tissue sarcoma cell lines treated in vitro for 6 hours with BO-112 or vehicle control

Project description:Impact of BO-112 on gene expression of sarcoma cell lines treated with BO-112 or control

2026-02-18 | GSE313237 | GEO

Bulk RNA-sequencing of soft tissue sarcomas from patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma

Project description:Bulk RNA-sequencing of soft tissue sarcomas from patients undergoing neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma

| PRJNA1425103 | ENA

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Project description:This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or gastroesophageal junction cancers. The objective is to reverse the primary resistance that a subgroup of patients from these tumors having microsatellite stability present to the PD-1 inhibitors. Treatment will be administered every 3 weeks, with the exception of the first cycle, in which BO-112 will be also administered on D8, for up to 2 years. The primary objective is overall response rate based on RECIST 1.1 and safety, specifically referred to treatment emergent adverse events (TEAEs) with severity ≥ Grade 3 related to the study treatment (NCI-CTCAE v 5.0). The secondary endpoints include other efficacy endpoints (duration of response, disease control rate, progression-free survival, overall survival at 6 months, all based on RECIST 1.1, and overall response rate based on a specific tumor assessment criteria to evaluate the response to immunotherapies, IRECIST) and safety, in this case considering the number and proportion of subjects with treatment TEAEs (any grade) . In addition, the changes in the tumor microenvironment induced by the injection of BO-112 will be also evaluated as exploratory endpoints.

| 2348431 | ecrin-mdr-crc

Project description:Spatial transcriptomics for neoadjuvant BO-112 and hypofractionated radiation therapy sarcoma

| PRJNA1380461 | ENA

Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response

Project description:This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the hypofractionated high dose radiation therapy and a rationale for adjuvant immunotherapy.

| 2189624 | ecrin-mdr-crc

Altererythrobacter sp. BO-6

Project description:Altererythrobacter sp. BO-6 Genome sequencing

| PRJNA608229 | ENA

Altererythrobacter sp. BO-6

Project description:Altererythrobacter sp. BO-6 Genome sequencing

| PRJNA560736 | ENA